Related Experiment Video
Updated: Feb 21, 2026
06:13
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.8K
Exercise after You Eat: Hitting the Postprandial Glucose Target
Melissa L Erickson1, Nathan T Jenkins2, Kevin K McCully2
1Department of Pathobiology, Cleveland Clinic Foundation, Cleveland, OH, United States.
Frontiers in Endocrinology
|October 5, 2017
Summary
Postmeal exercise can lower blood sugar spikes after eating. Its effectiveness depends on the exercise intensity and duration versus the magnitude and length of the blood sugar increase.
Area of Science:
- Exercise Physiology
- Metabolic Health
- Endocrinology
Background:
- Postprandial hyperglycemia is a risk factor for type 2 diabetes.
- Lifestyle interventions, including exercise, are crucial for glucose management.
- The relationship between exercise characteristics and glucose attenuation needs further elucidation.
Purpose of the Study:
- To propose a novel hypothesis regarding the determinants of postmeal exercise efficacy.
- To investigate the relationship between exercise bout parameters and postprandial glucose response.
Main Methods:
- This study is a hypothesis-driven discussion.
- It synthesizes existing knowledge on exercise physiology and glucose metabolism.
- It proposes a functional relationship based on theoretical considerations.
Main Results:
- The effect size of postmeal exercise in attenuating postprandial glucose is hypothesized to be a function of the exercise bout.
- This effect is also proposed to be dependent on the size of the postprandial glucose response, specifically its peak and duration.
Conclusions:
- Postmeal exercise effectiveness is not uniform and likely varies based on individual glucose excursions.
- Understanding this functional relationship can optimize exercise prescriptions for glucose control.
- Further research is warranted to empirically test this hypothesis.
Keywords:
continuous glucose monitoringglycemic controlpostmeal exercisepostprandial glucosetype 2 diabetesMore Related Videos
Related Concept Videos
01:16Hormones Regulating Blood Glucose
7.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.2K
01:02Glucose Homeostasis: Regulation of Blood Glucose
4.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.6K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
621
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
621
01:15Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
01:18Metabolic States of the Body: The Postabsorptive State
1.4K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.4K
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K